Unlocking Alzheimer’s Mysteries: How PHGDH Changes the Game Alzheimer’s disease remains one of the most challenging neurodegenerative conditions, particularly in its late-onset form (LOAD), which strikes millions without clear genetic risk factors. Recent rese... Alzheimer's amyloid-beta biomarkers neurodegeneration PHGDH therapeutics transcriptional regulation
MIT Researchers Chart New Paths for Alzheimer’s Drug Targets Beyond Amyloid Alzheimer’s disease has challenged the scientific community for decades, especially as treatments focused on amyloid plaques have not delivered the hoped-for results. In a promising shift, researchers... Alzheimer's computational biology DNA repair drug discovery genetics MIT neurodegeneration RNA modification
How Sugars on Cell Surfaces Could Unlock New Paths to Brain Resilience What if a crucial piece in the puzzle of brain aging has been hiding in plain sight, overlooked sugars on the surfaces of our brain cells. While past research zeroed in on proteins and DNA, emerging s... Alzheimer's blood-brain barrier brain aging cell surface sugars cognitive decline drug delivery glycocalyx neurodegeneration
New Genetic Pathways Offer Hope for Alzheimer’s Drug Development Alzheimer’s disease is a condition that affects millions globally and has traditionally been linked to amyloid plaques in the brain. Most drug development efforts have targeted these plaques but real-... Alzheimer's computational biology DNA repair drug discovery genetics neurodegeneration RNA modification